Bepotastine besilate

Name: Bepotastine besilate
Brand: MedChemExpress
SKU: HY-A0015
Rating: 4.5 (1 reviews)

Cat. No.: HY-A0015 Purity: 99.77%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Bepotastine besilate is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research.

For research use only. We do not sell to patients.

Bepotastine besilate Chemical Structure

CAS No. : 190786-44-8

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 33	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 33	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	USD 30	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Bepotastine besilate:

(Rac)-Bepotastine besilate Get quote
Bepotastine Get quote
Bepotastine tosylate Get quote
Bepotastine besilate (Standard) Get quote

1 Publications Citing Use of MCE Bepotastine besilate

•J Med Chem. 2021 Mar 11;64(5):2725-2738. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Histamine Receptor Isoform Specific Products:

View All Isoforms

H₁ Receptor H₂ Receptor H₃ Receptor H₄ Receptor Histamine Receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

H₁ Receptor

In Vitro

Bepotastine besilate (10, 100, 1000 μM; preincubates for 120 min) decreases the release of histamine induced by A23187 treatment, which reaches a statistically significant reduces level at 1000 μM^[1].
Bepotastine besilate (50 μM; 1 h) suppresses the expression of NGF mRNA in NHEKs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	NHEKs
Concentration:	50 µM (preincubation)
Incubation Time:	1 h
Result:	Suppressed the expression of NGF mRNA in NHEKs.

Western Blot Analysis^[1]

Cell Line:	RPMCs
Concentration:	10, 100, 1000 µM
Incubation Time:	120 min (preincubate)
Result:	Decreased the release of histamine.

In Vivo

Bepotastine besilate (10 g/L; eye drop; 3 times at intervals of 20 min in one eye) demonstrates significant inhibition of PAF-induced conjunctival eosinophil infiltration^[1].
Bepotastine besilate (3 mg/kg; p.o.; once) suppresses scratching behavior to a frequency of 59.0 and a duration of 14.57 seconds, which are almost the same levels compares with the control^[3].
Bepotastine besilate (10 mg/kg; p.o.; once) significantly suppresses serum LTB 4 levels to 711.3 pg/mL at 1 h and 858.8 pg/mL at 2 h in NC/Nga mice with a rash^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Guinea pigs (6-week-old)^[1].
Dosage:	10 g/L (1.0% (w/v)) for 10 µL.
Administration:	Eye drop; 3 times at intervals of 20 min (in one eye).
Result:	Inhibited PAF-induced conjunctival eosinophil infiltration.

Animal Model:	Male BALB/c mice(12-week-old); NC/Nga mice^[3].
Dosage:	3, 10 mg/kg
Administration:	Oral administration; once (1 h before induces scratching behavior of Male BALB/c mice).
Result:	Significantly inhibited histamine-mediated scratching behavior in male BALB/c mice. Significantly suppressed serum LTB 4 levels in NC/Nga mice with a rash.

Clinical Trial

Molecular Weight

547.06

Formula

C₂₇H₃₁ClN₂O₆S

CAS No.

190786-44-8

Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C(CCCN1CCC(CC1)O[C@H](C2=NC=CC=C2)C3=CC=C(C=C3)Cl)O.O=S(C4=CC=CC=C4)(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (182.80 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8280 mL	9.1398 mL	18.2795 mL
5 mM	0.3656 mL	1.8280 mL	3.6559 mL
10 mM	0.1828 mL	0.9140 mL	1.8280 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.77%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (246 KB) HNMR (275 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

References

[1]. Kida T, et al. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res. 2010 Jul;91(1):85-91. [Content Brief]

[2]. Kamata Y, et al. Bepotastine besilate downregulates the expression of nerve elongation factors in normal human epidermal keratinocytes. J Dermatol Sci. 2018 Apr 23:S0923-1811(18)30186-5. [Content Brief]

[3]. Tanizaki H, et al. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int Arch Allergy Immunol. 2008;145(4):277-82. [Content Brief]

[4]. Jon I Williams, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010 Oct;26(10):2329-38. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.8280 mL	9.1398 mL	18.2795 mL	45.6988 mL
	5 mM	0.3656 mL	1.8280 mL	3.6559 mL	9.1398 mL
	10 mM	0.1828 mL	0.9140 mL	1.8280 mL	4.5699 mL
	15 mM	0.1219 mL	0.6093 mL	1.2186 mL	3.0466 mL
	20 mM	0.0914 mL	0.4570 mL	0.9140 mL	2.2849 mL
	25 mM	0.0731 mL	0.3656 mL	0.7312 mL	1.8280 mL
	30 mM	0.0609 mL	0.3047 mL	0.6093 mL	1.5233 mL
	40 mM	0.0457 mL	0.2285 mL	0.4570 mL	1.1425 mL
	50 mM	0.0366 mL	0.1828 mL	0.3656 mL	0.9140 mL
	60 mM	0.0305 mL	0.1523 mL	0.3047 mL	0.7616 mL
	80 mM	0.0228 mL	0.1142 mL	0.2285 mL	0.5712 mL
	100 mM	0.0183 mL	0.0914 mL	0.1828 mL	0.4570 mL